There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.
intellectual property for pharmaceuticals
January 30, 2017 4:46PM
January 24, 2017 1:00AM
October 14, 2016 1:30AM
Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals
July 22, 2013 2:00AM
Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP). Two new essays on the cost and benefits of stronger protection suggest Canadians would be far better off, in both economic and health terms, with an IP protection regime for pharmaceutical innovators that was more closely aligned with international standards.